Response to Comments: MolDX: Molecular Testing for Identification and Management of Hereditary Transthyretin Amyloidosis

This document (A60202) records the response to public comments on the MolDX Local Coverage Determination for molecular testing related to hereditary transthyretin amyloidosis. The comment period ran from August 29, 2024 to October 12, 2024; the notice period for LCD L39950 begins July 3, 2025 and the LCD becomes effective August 17, 2025. The document contains no clinical coverage criteria or claim-level documentation requirements.

"The public comment period for the MolDX Local Coverage Determination (LCD) on molecular testing for hereditary transthyretin amyloidosis began 2024-08-29 and ended 2024-10-12."

Sign up to see full coverage criteria, indications, and limitations.